VIVE.ST
Healthcare Drug Manufacturers - Specialty & GenericVivesto AB
SEK 7.49
+0.33 +4.61% today
Price History
Not enough data
Key Stats
Market Cap
82.92M
Avg Volume
8,465
EPS
-SEK 4.12
52W High
SEK 23.76
52W Low
SEK 7.00
Div. Yield
0.0%
Valuation
Forward P/E
-74.90
P/B Ratio
32.28
P/S Ratio
10365.57
EV/EBITDA
-1.84
EV/Revenue
7080.34
Margins
Gross Margin 100.0%
Operating Margin (107825.0%)
Net Margin 0.0%
EBITDA Margin 0.0%
Growth & Returns
Return on Equity
(21.1%)
Return on Assets
(12.2%)
Liquidity & Leverage
Current Ratio
2.48
Quick Ratio
2.39
Total Cash
23.51M
Total Debt
0
About
Vivesto AB develops, develops, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product, Paccal Vet, is a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma. The company also provides Apealea, an injectable formulation of paclitaxel for the treatment of various cancers. In addition, it develops Cantrixil, a drug candidate for the treatment of advanced cancer, and Docetaxel micellar for the treatment of prostate cancer. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was founded in 1988 and is headquartered in Solna, Sweden.
www.vivesto.com